

PGT-121 LO6 heavy chain variable domain sequence

Q	M	Q	L	Q	E	S	G	P	G	L	V	K	P	S	E	T	L	S	L	T	C	S	V	S	G	A	S	I	S
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30
D	S	Y	W	S	W	I	R	R	S	P	G	K	G	L	E	W	I	G	Y	V	H	K	S	G	D	T	N	Y	S
31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60
P	S	L	K	S	R	V	N	L	S	L	D	T	S	K	N	Q	V	S	L	S	L	V	A	A	T	A	A	D	S
61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	82A	82B	82C	83	84	85	86	87
G	K	Y	Y	C	A	R	T	L	H	G	R	R	I	Y	G	I	V	A	F	N	E	W	F	T	Y	F	Y	M	D
88	89	90	91	92	93	94	95	96	97	98	99	100	100A	100B	100C	100D	100E	100F	100G	100H	100I	100J	100K	100L	100M	100N	100O	100P	101
V	W	G	N	G	T	Q	V	T	V	S	S																		
102	103	104	105	106	107	108	109	110	111	112	113																		

PGT-121 LO6 light chain variable domain sequence

-	-	-	-	-	-	-	-	S	D	I	S	V	A	P	G	E	T	A	R	I	S	C	G	E	K	S	L	G	S	R
1	2	3	4	5	6	7	8	9	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
A	V	Q	W	Y	Q	H	R	A	G	Q	A	P	S	L	I	I	Y	N	N	Q	D	R	P	S	G	I	P	E	R	
32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	
F	S	G	S	P	D	S	P	F	G	T	T	A	T	L	T	I	T	S	V	E	A	G	D	E	A	D	Y	Y	C	
62	63	64	65	66	67	67a	67b	67c	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	
H	I	W	D	S	R	V	P	T	K	W	V	F	G	G	G	T	T	L	T	V	L	G								
89	90	91	92	93	94	95	95a	95b	95c	96	97	98	99	100	101	102	103	104	105	106	107	108								

Figure 1




Figure 2

DSF Fab TM Paired Mutant Analysis, Heavy Chain




Figure 3

4/32




Figure 4




Figure 5




Figure 6





Figure 7

8/32

*Figure 8A*

Human FcγRIIIA-176F ELISA




Figure 8B

10/32

Human FcγRIIIA-176V




Figure 8C

Human FcγRIIA-167H



Figure 8D

Human FcγRIIA-167R




Figure 8E




Figure 8F

Human Fc γ RIIIB-NA1




Figure 8G

Human Fc γ RIIB-NA2






Figure 8H

16/32

Antibodies Binding to Recombinant HIV Env BaL in Transfected HEK293T Cells

*Figure 9*

Fold Change in Recombinant HIV Env Binding EC50

*Figure 10*




Figure 11








Figure 12


19/32

*Figure 13**Figure 14*

20/32

*Figure 15**Figure 16*

21/32

*Figure 17*








Figure 18A

Figure 18B


23/32

*Figure 19A**Figure 19B*

24/32


*Figure 20**Figure 21*

25/32


*Figure 22*

26/32


human FcRn ELISA

*Figure 23A*


Human FcRn ELISA

*Figure 23B*

27/32

*Figure 24*



28/32

*Figure 25*

29/32

Effector Cell Activation

(HT593 Env transfected HEK293T)

*Figure 26***ADCC, US657 virus***Figure 27*




Figure 28





Figure 29A

32/32

*Figure 29B*